|
0
|
|
Safety, Feasibility, and Rifapentine Plasma Concentration in Chinese Children With 1 Month of Daily Rifapentine Plus Isoniazid for Tuberculosis Infection.
(academic.oup.com)
|
Liu W
…
Zhang P
Clinical Infectious Diseases
2026-02-04
|
#pharmacokinetics
#clinical trial
#chemotherapy
#pediatrics
#tb
|
|
0
|
|
Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell-Depleting Therapy With COVID-19: A Target Trial Emulation Study.
(academic.oup.com)
|
Calabrese C
…
Wang XF
Clinical Infectious Diseases
2026-02-04
|
#infection
#covid-19
#clinical trial
#antiviral
#immunocompromised
|
|
0
|
|
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study.
(academic.oup.com)
|
Nyein PP
…
Matthews GV
Clinical Infectious Diseases
2026-02-04
|
#amr
#clinical trial
#treatment
#hiv
|
|
0
|
|
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years.
(academic.oup.com)
|
Mayer EF
…
Priddy F
Clinical Infectious Diseases
2026-02-04
|
#vaccination
#clinical trial
#rna
#immunogenicity
#rsv
|
|
0
|
|
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
(academic.oup.com)
|
Kim AY
…
Naggie S
Clinical Infectious Diseases
2026-02-04
|
#clinical trial
#treatment
#antiviral
#hepatitis c
|
|
0
|
|
First-in-human safety and pharmacokinetics of MK-7602, the antimalarial inhibitor of plasmepsins IX/X, in single- and multiple-ascending-dose studies.
(journals.asm.org)
|
Stanley SE
…
Nussbaum J
Antimicrobial Agents and Chemotherapy
2026-02-04
|
#pharmacokinetics
#toxicology
#malaria
#clinical trial
|